FDA Issues Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products and Devices | McDermott Will & Emery

Over the past few years, the life sciences and healthcare industries have experienced a notable increase in focus and interest in decentralized clinical trials (DCTs), in which some or all of the trial-related activities occur at locations other than traditional in-person clinical trial sites,…

Source: www.jdsupra.com – Read more